Claim Missing Document
Check
Articles

Found 4 Documents
Search

Profil Pengobatan Dispepsia Pasien Rawat Inap di RSUD Budhi Asih periode Juli 2019 – Juni 2020 Fransiska - Sitompul; Dwikarlina Hidayat; Linggom Kurniaty; Nadya Theresia Muraga
Jurnal Ilmiah Kesehatan Vol 21 No 03 (2022): Jurnal Ilmiah Kesehatan terbitan Desember Volume 21 Nomor 03 Tahun 2022
Publisher : STIKIM Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33221/jikes.v21i03.2041

Abstract

Dispepsia merupakan sekumpulan gejala yang menimbulkan sensasi tidak nyaman di bagian saluran pencernaan, umumnya dirasakan di daerah epigastrium, antara bagian bawah prosessus xiphoideus sampai dengan umbillicus. Istilah dispepsia berasal dari bahasa yunani, terdiri dari 2 suku kata yaitu (“dys” artinya buruk ; “pepsis” artinya pencernaan). Sekumpulan gejala klinis yang dapat dirasakan antara lain seperti sensasi terbakar dan nyeri epigastrium, mual, muntah, kembung, penumpukan gas di epigastrium, kekenyangan dan sendawa. Penelitian ini bertujuan untuk mengetahui faktor-faktor yang berhubungan dengan pengobatan dispepsia pasien rawat inap di RSUD Budhi Asih periode Juli 2019 – Juni 2022. Penelitian ini dilakukan dengan desain cross sectional retrospektif. Sampel terdiri dari 139 rekam medik pasien dispepsia diambil secara total sampling. Hasil penelitian diperoleh dispepsia dialami perempuan (58,99%), keluhan utama mual (74,82%), terapi obat antiulkus: sucralfate oral (25,77%), dan terapi prokinetik : ondansetron (33,73%), lama rawat 1-3 hari (71,22%), variasi jumlah obat dispepsia dan anti ulkus menunjukkan jumlah obat 1-3 (92,81%), bentuk sediaan obat injeksi (50,34%), dan bentuk tablet (26,68%). Kesimpulan penelitian adalah faktor yang berhubungan dengan pengobatan dispepsia pasien rawat inap di RSUD Budhi Asih periode Juli 2019 – Juni 2022 dipengaruhi jenis kelamin, gejala klinis yang dikeluhkan, kelas terapi antikulkus, variasi jumlah obat dan bentuk sediaan obat.
Teratai (Nelumbo nucifera Gaertn.): Botani, Potensi Pemanfaatan, dan Metabolit Sekunder Marina Silalahi; Sri Mulyaningsih; Linggom Kurniaty
Pro-Life Vol. 12 No. 3 (2025): November
Publisher : Program Studi Pendidikan Biologi Fakultas Keguruan dan Ilmu Pendidikan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33541/pro-life.v12i3.6734

Abstract

Nelumbo nucifera Gaertn is one of the aquatic plants used for food, medicine, culture, and religion. This study aims to explain the botany, utilization, bioactivity, and secondary metabolites of N. nucifera. This study is based on a literature review published online using the keywords N. nucifera, uses of N. nucifera, and bioactivity of N. nucifera. Data analysis was carried out qualitatively to describe the botany, utilization, and secondary metabolites of N. nucifera. In taxonomy, N. nucifera is grouped in the Nelumbonaceae family. N. nucifera is a perennial aquatic plant with a rhizome stem and a single, round leaf with large pink or white flower petals. In traditional medicine, N. nucifera is used to treat various diseases such as inflammation, insomnia, cardiovascular issues, hyperlipidemia, nervous disorders, emollient and diuretic effects, diarrhoea, dyspepsia, hematuria, fever, epilepsy, hypertension, and obesity. N. nucifera bioactivity as an antioxidant, anti-cancer/tumor, neuroprotective, anti-inflammatory, increases sperm motility, anti-diabetes mellitus, and skin whitener. Lotus has flowers, seeds, leaves, fruits, and rhizomes that can be eaten because they have more carbohydrates, proteins, and vitamins. Alkaloids, polyphenols, terpenoids, steroids, and glycosides are responsible for its various biological and pharmacological activities. The potential for utilizing N. nucifera for food diversification, vegetable protein sources, and skin whitening needs to be studied further.
COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF OLD AND NEW TB DRUGS IN THE TREATMENT OF PULMONARY TUBERCULOSIS Romauli Lumbantobing; Linggom Kurniaty; Welly Salutondok; Tiroy Sari B. Simanjuntak
SYNTHESIS Global Health Journal Volume 3, Issue 2, 2025
Publisher : SYNTIFIC

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61543/syn.v3i2.148

Abstract

Background. The availability of effective drug regimens of Pulmonary tuberculosis (TB) poses a global health challenge. Traditional first-line therapies-isoniazid, rifampicin, pyrazinamide, and ethambutol-remain the cornerstone of TB management due to their accessibility and documented cure rates exceeding 85%. Nevertheless, limitations such as variable drug metabolism, patient non-adherence, and the emergence of multidrug-resistant strains have prompted evaluation of newer treatment combinations to optimize efficacy, safety, and duration. The purpose was to compare the effectiveness of older first-line tuberculosis (TB) drug regimens with newer therapeutic regimens in the treatment of pulmonary tuberculosis. Research Method. This narrative review synthesizes findings from five peer-reviewed studies comparing the effectiveness and safety profiles of conventional and novel TB drug regimens. The review focused on regimen composition, treatment duration, bacteriological clearance, hepatotoxicity, and patient adherence outcomes. Findings. The inclusion of pyrazinamide in six-month regimens significantly accelerated bacterial clearance without increasing hepatic toxicity compared to traditional nine-month isoniazid–rifampicin regimens. Additionally, shorter rifampin-based regimens for latent TB demonstrated higher treatment completion rates and fewer adverse effects than isoniazid monotherapy. Emerging regimens, such as fluoroquinolone-based HRM therapies and the novel BPaL combination (bedaquiline, pretomanid, and linezolid), yielded comparable or improved outcomes, with BPaL achieving success rates up to 93% in drug-resistant TB cases. Conclusion. Current evidence supports the strategic adaptation of TB therapy to balance efficacy, tolerability, and treatment duration. Incorporating newer drug combinations, particularly for drug-resistant TB, enhances adherence and clinical outcomes, underscoring the need for individualized treatment protocols aligned with evolving resistance patterns and patient profiles.
Evaluasi Cakupan Imunisasi Dasia Berdasarkan Data Program Rutin Sebelum dan Pascapandemi COVID-19 Fransiska Sitompul; Mairani Sakinah; Hertina Silaban; Linggom Kurniaty
Nursing Care and Health Technology Journal (NCHAT) Vol. 7 No. 1 (2027): Nursing and Health Care Technology-January to June Period
Publisher : Progres Ilmiah Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56742/nchat.v7i1.349

Abstract

Imunisasi adalah upaya untuk meningkatkan kekebalan seseorang secara aktif terhadap suatu penyakit, sehingga suatu saat terpajan dengan penyakit tersebut tidak akan sakit atau hanya mengalami sakit ringan. Adanya Covid-19 secara global sejak ditetapkan sebagai Public Health Emergency of International Concern (PHEIC) pada 30 Januari 2020 dan sebagai pandemi pada 11 Maret 2020 oleh WHO, memberikan dampak pada pelaksanaan program kesehatan khususnya pelayanan imunisasi dan surveilans PD3I. Berdasarkan data dari GAVI, WHO dan UNICEF menyebutkan bahwa setidaknya 80 juta anak usia kurang dari 1 tahun memiliki risiko untuk menderita penyakit difteri, campak dan polio akibat terganggunya pelayanan imunisasi rutin di tengah pandemi Covid -19. Penelitian ini bertujuan mengevaluasi capaian program imunisasi dasar usia 0 – 24 bulan di Puskesmas Kecamatan Cakung (Periode Covid-19 tahun 2020 dan 2023). Desain penelitian yaitu desain repeated cross-sectional descriptive study dengan pendekatan survei observasional. Penelitian dilakukan di Puskesmas Kecamatan Cakung, Jakarta Timur dan lama penelitian dari Juli 2023 – Juni 2024. Teknik pengambilan sampel dilakukan dengan total sampling. Data diambil dari rekam medik dan sistem SiCantik. Data di analisis univariat, sebagai analisis deskriptif (Microsoft Excel) dengan menggunakan rumus cakupan imunisasi. Hasil penelitian menunjukkan capaian imunisasi dasar tahun 2020 tercapai sebanyak  9.1% dan tahun 2023 tidak tercapai sebanyak 7.4%; capaian imunisasi dasar lanjutan tahun 2020 tidak tercapai sebanyak  6%  dan tahun 2023 tercapai sebanyak 8%.